Shares of Champions Oncology CSBR were unchanged in after-market trading after the company reported Q1 results.
Earnings per share increased 120.00% year over year to $0.01, which missed the estimate of $0.02.
Revenue of $9,547,000 rose by 41.71% from the same period last year, which beat the estimate of $8,710,000.
Earnings guidance hasn't been issued by the company for now.
Champions Oncology hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Sep 14, 2020
Time: 04:30 PM
ET Webcast URL: https://www.championsoncology.com/upcoming-events
Company's 52-week high was at $10.89
Company's 52-week low was at $4.02
Price action over last quarter: down 11.45%
Champions Oncology Inc is a US-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.